Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8833038rdf:typepubmed:Citationlld:pubmed
pubmed-article:8833038lifeskim:mentionsumls-concept:C0015967lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0021753lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0021760lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0600251lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0927232lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0035696lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0017710lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0599946lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C1550147lld:lifeskim
pubmed-article:8833038lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:8833038pubmed:issue3lld:pubmed
pubmed-article:8833038pubmed:dateCreated1997-5-28lld:pubmed
pubmed-article:8833038pubmed:abstractTextSubchronic (36 h) exposure of rats to corticosterone (CS) (100 mg/pellet,subcutaneously), blocked the pyrogenic response to recombinant human interleukin 113 (rhIL-1 beta, 5 mu g/kg, ip.). CS treatment reduced the basal mRNA levels of IL-1 alpha and IL-1 beta, but elevated the mRNA levels of IL-6 in the hypothalamus and hippocampus as shown by RT-PCR. The CS treatment clamped the cytokine mRNA levels, and injection of rhIL-1 beta to CS treated rats did not significantly affect these altered mRNA levels. IL-6 bioactivity in serum was not significantly changed by CS treatment, but increased 50 times upon injection of rhIL-1 beta. rhIL-1 beta caused a significantly lower induction of serum IL-6 levels in CS pretreated rats (9-fold). The pyrogenic response to injection of rhIL-1 beta has returned 5 days after the removal of the corticosterone pellet, and the hypothalamic cytokine mRNA levels (IL-1 alpha, IL-1 beta and IL-6) have returned to basal. These results suggest that altered and clamped hypothalamic IL-1 alpha, IL-1 beta and IL-6 mRNA levels may be involved in the antipyretic effects of a pretreatment with high doses of CS and that these CS effects are rapidly reversible.lld:pubmed
pubmed-article:8833038pubmed:languageenglld:pubmed
pubmed-article:8833038pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:citationSubsetIMlld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833038pubmed:statusMEDLINElld:pubmed
pubmed-article:8833038pubmed:monthMarlld:pubmed
pubmed-article:8833038pubmed:issn1043-4666lld:pubmed
pubmed-article:8833038pubmed:authorpubmed-author:BartfaiTTlld:pubmed
pubmed-article:8833038pubmed:authorpubmed-author:ChanEElld:pubmed
pubmed-article:8833038pubmed:authorpubmed-author:GattoIIlld:pubmed
pubmed-article:8833038pubmed:authorpubmed-author:AlheimKKlld:pubmed
pubmed-article:8833038pubmed:authorpubmed-author:LundkvistJJlld:pubmed
pubmed-article:8833038pubmed:issnTypePrintlld:pubmed
pubmed-article:8833038pubmed:volume8lld:pubmed
pubmed-article:8833038pubmed:ownerNLMlld:pubmed
pubmed-article:8833038pubmed:authorsCompleteYlld:pubmed
pubmed-article:8833038pubmed:pagination227-37lld:pubmed
pubmed-article:8833038pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:meshHeadingpubmed-meshheading:8833038-...lld:pubmed
pubmed-article:8833038pubmed:year1996lld:pubmed
pubmed-article:8833038pubmed:articleTitleSubchronic glucocorticoid pretreatment reversibly attenuates IL-beta induced fever in rats; IL-6 mRNA is elevated while IL-1 alpha and IL-1 beta mRNAs are suppressed, in the CNS.lld:pubmed
pubmed-article:8833038pubmed:affiliationDepartment of Neurochemistry and Neurotoxicology, Stockholm University, Sweden.lld:pubmed
pubmed-article:8833038pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8833038lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8833038lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8833038lld:pubmed